No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract

Planta Medica

Volumn 71, Issue 4, 2005, Pages 331-337

  Arold, Gerhard ^a   Donath, Frank ^a   Maurer, Agathe ^a   Diefenbach, Konstanze ^a   Bauer, Steffen ^a   Henneicke Von Zepelin, Hans Heinrich ^b   Friede, Michael ^b   Roots, Ivar ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Schaper & Brummer GmbH & Co KG   (Germany)

Author keywords

Clinical trial; Clusiaceae; Drug safety; Hypericum perforatum; Interaction; St. John's wort

Indexed keywords

4 HYDROXYTOLBUTAMIDE; ALPRAZOLAM; CAFFEINE; COFFEINUM PURUM; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DIGOREGEN; DIGOXIN; GLYCOPROTEIN P; HYPERFORIN; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; PARAXANTHINE; PLACEBO; PREGNANE X RECEPTOR; PSEUDOHYPERICIN; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG HALF LIFE; FEMALE; GENE EXPRESSION REGULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE DRUG DOSE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE;

ADULT; ALPRAZOLAM; ANTI-ANXIETY AGENTS; AREA UNDER CURVE; CAFFEINE; CARDIOTONIC AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; DIGOXIN; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; HYPERICUM; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS; TOLBUTAMIDE; TREATMENT OUTCOME;

CLUSIACEAE; HYPERICUM PERFORATUM;

EID: 18744369624     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-864099     Document Type: Article

References (20)

1. Linde K, Mulrow CD. St John's wort for depression. Cochraine Database Syst Rev 2000; 2: CD000448
2. Johne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999; 66: 338-45
3. Perloff MD, von Moltke LL, Störmer E, Shader RI, Greenblatt DJ. Saint John's wort: An in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol 2001; 134: 1601-8
4. Mai I, Krüger H, Budde K, Johne A, Brockmöller J, Neumayer HH et al. Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin. Int J Clin Pharm Ther 2000; 38: 500-2
5. Bolley R, Zulke C, Kammerl M, Fischereder M, Kramer BK. Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John's wort. Transplantation 2002; 73: 1009
6. Johne A, Schmider J, Brockmöller J, Stadelmann AM, Störmer E, Bauer S et al. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum). J Clin Psychopharmacol 2002; 22: 46-54
7. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Lalloon J. Indinavir concentrations and St. John's wort. Lancet 2000; 355: 547-8
8. Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002; 71: 411-3
9. Meier B. Comparing phytopharmaceuticals: the example of St John's wort. Adv Ther 2001; 18: 35-46
10. Bundesanzeiger. Bekanntmachung über die Zulassung und Registrierung von Arzneimitteln: Aufbereitungsmonographie der Kommission E, Hyperici herba (Johanniskraut). BAnz Nr. 43, 02.03.1989.
11. Bauer S, Störmer E, Graubaum HJ, Roots I. Determination of hyperforin, hypericin, and pseudohypericin in human plasma using high-performance liquid chromatography analysis with fluorescence and ultraviolet detection. Chromatogr B Biomed Sci Appl 2001; 765: 29-35
12. Kirchheiner J, Bauer S, Meineke I, Rohde W, Prang V, Meisel C et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 2002; 12: 101-9
13. Friede M, Liske E, Wüstenberg P. Therapeutic effects of Hypericum perforatum in the treatment of depressive disorders. J Cereb Blood Flow Metab 1999; 19 (suppl. 1): 116
14. Bernhardt M, Liske E. Antidepressive Therapie mit Johanniskraut-Extrakt unter besonderer Berücksichtigung von zwei unterschiedlichen Dosierungsschemata. Jatros Neurologie 1996; 12: 43-8
15. Zhou S, Chan E, Pan SQ, Huang M, Lee EJ. Pharmacokinetic interactions of drugs with St. John's wort. Psychopharmacol 2004; 18: 262-76
16. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001; 70: 317-26
17. Uehleke B, Mueller SC, Woehling H, Petzsch M, Riethling A-K et al. Interaction of St. John's wort with digoxin in relation to dosage and formulation. Phytomedicine 2000; 7 (suppl. II): 20
18. Loyda R, Gruber K. Safety and tolerability of different Hypericum extracts. Phytomedicine 2000; 7 (suppl. II): 20
19. Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000; 294: 88-95
20. Wentworth JM, Agostini M, Love J, Schwabe JW, Chatterjee VK. St. John's wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 2000; 166: R11-6